BlackRock’s Kiromic BioPharma, Inc. Common Stock KRBP Stock Holding History

BlackRock’s Portfolio KRBP Stock Details KRBP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-809	Closed	-$2.2K	–	5642
2023 Q2	$2.2K	Hold	809	–	–	﹤0.01%	5367
2023 Q1	$3.12K	Buy	+809	New	+$4.28K	﹤0.01%	5417
2022 Q2	–	Sell	-1,152	Closed	-$30K	–	6052
2022 Q1	$30K	Sell	1,152 -57	-5%	-$1.69K	﹤0.01%	5513
2021 Q4	$55K	Buy	1,209 +187	+18%	+$12.7K	﹤0.01%	5388
2021 Q3	$94K	Buy	1,022 +701	+218%	+$72.5K	﹤0.01%	5153
2021 Q2	$46K	Buy	321 +150	+88%	+$37.6K	﹤0.01%	5199
2021 Q1	$48K	Buy	171 +53	+45%	+$15.5K	﹤0.01%	4924
2020 Q4	$30K	Buy	+118	New	+$33.5K	﹤0.01%	4733

BlackRock's KRBP Position: Q3 2023 in Review

BlackRock sold out of Kiromic BioPharma, Inc. Common Stock (KRBP) in Q3 2023, closing a stake of 809 shares — an estimated $2.2K sold.

BlackRock first reported a position in KRBP in Q4 2020 and held it in 8 quarters. The position peaked at $94K in Q3 2021. 0 funds tracked by Wall St. Rank hold KRBP as of Q3 2023.

BlackRock reported no remaining Kiromic BioPharma, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
BlackRock sold 809 Kiromic BioPharma, Inc. Common Stock shares in Q3 2023, an estimated $2.2K.
BlackRock first reported a position in Kiromic BioPharma, Inc. Common Stock in Q4 2020 and held it in 8 quarters.
BlackRock's Kiromic BioPharma, Inc. Common Stock position peaked at $94K in Q3 2021.
0 funds tracked by Wall St. Rank held Kiromic BioPharma, Inc. Common Stock as of Q3 2023.

Based on BlackRock's 13F filing for Q3 2023, filed 13 Nov 2023.